Zioptan Solution/ Drops
NDC Package 82584-609-30
Package Information
Zioptan (tafluprost) solution/ dropses is tafluprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). This formulation utilizes a solution/ drops delivery system. Marketed by Thea Pharma Inc., this product is identified by NDC 82584-609 and is authorized under FDA application NDA202514.
Identification & Billing
- RxCUI: 1244611 - tafluprost 0.0015 % Ophthalmic Solution
- RxCUI: 1244611 - tafluprost 0.015 MG/ML Ophthalmic Solution
- RxCUI: 1244616 - ZIOPTAN 0.0015 % Ophthalmic Solution
- RxCUI: 1244616 - tafluprost 0.015 MG/ML Ophthalmic Solution [Zioptan]
- RxCUI: 1244616 - Zioptan 0.0015 % Ophthalmic Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 82584 - Thea Pharma Inc.
- 82584-609 - Zioptan
- 82584-609-30 - 3 POUCH in 1 CARTON / 10 VIAL, SINGLE-USE in 1 POUCH (82584-609-01) / .3 mL in 1 VIAL, SINGLE-USE
- 82584-609 - Zioptan
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 82584-609-30 identifies a specific commercial package of 3 pouch in 1 carton / 10 vial, single-use in 1 pouch (82584-609-01) / .3 ml in 1 vial, single-use of Zioptan, a human prescription drug labeled by Thea Pharma Inc.. This solution/ drops is formulated for ophthalmic use and contains tafluprost as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Thea Pharma Inc. on October 28, 2022. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Tafluprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.
How is this Thea Pharma Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 82584060930. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.